13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001617201
Total reported value
$580.4M
$580.4M
38 檔
20.0%
The Q1 2025 SEC filing reveals that Prosight Management, LP held a total portfolio value of $580.4M, covering 38 public equity positions.
In Q1 2025, Prosight Management, LP displayed an active expansion posture, initiating 38 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including LKFT, MGTX, BBIO) accounted for 20.0% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 10.85% | +2.93% | +28.28% | |
| 2 | MGTX | MeiraGTx Holdings plc | Stock-Other | 8.22% | -3.52% | -15.93% | |
| 3 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 6.93% | — | -38.69% | |
| 4 | JANX | Janux Therapeutics Inc | Stock-Other | 6.12% | +1.98% | +109.21% | |
| 5 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 6.05% | -0.82% | EXIT | |
| 6 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 5.08% | — | -23.90% | |
| 7 | KURA | Kura Oncology Inc | Stock-Other | 4.51% | -0.66% | +56.85% | |
| 8 | ✓ | Adc Therapeutics SA | Stock-Other | 4.42% | -3.66% | +0.29% | |
| 9 | ZYME | Zymeworks Inc | Stock-Other | 3.75% | +0.83% | +16.74% | |
| 10 | AM6 | Amicus Therapeutics Inc | Stock-Other | 3.70% | — | +49.93% | |
| 11 | ICLR | ICON Public Limited Company | Stock-Healthcare | 3.46% | — | -29.30% | |
| 12 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 3.24% | +0.01% | +35.94% | |
| 13 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 2.89% | — | -58.09% | |
| 14 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.66% | — | — | |
| 15 | SDGR | Schrodinger Inc | Stock-Other | 2.50% | -0.95% | EXIT | |
| 16 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.46% | +1.57% | -1.73% | |
| 17 | TECX | Tectonic Therapeutic Inc | Stock-Other | 2.32% | -0.16% | — | |
| 18 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.28% | +0.86% | — | |
| 19 | STTK | Shattuck Labs Inc | Stock-Other | 2.07% | +1.84% | — | |
| 20 | ABCL | Abcellera Biologics Inc | Stock-Other | 2.06% | — | -61.69% | |
| 21 | IMVT | Immunovant Inc | Stock-Other | 2.02% | -0.72% | EXIT | |
| 22 | PRTA | Prothena Corporation plc | Stock-Other | 1.66% | — | -2.39% | |
| 23 | LIVN | LivaNova PLC | Stock-Other | 1.64% | — | +81.86% | |
| 24 | HAE | Haemonetics Corp/mass | Stock-Other | 1.37% | — | +40.04% | |
| 25 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.06% | — | -45.50% | |
| 26 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 1.00% | -0.02% | +113.01% | |
| 27 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.82% | — | +0.64% | |
| 28 | CDNA | Caredx Inc | Stock-Other | 0.80% | — | +70.74% | |
| 29 | BHVN | Biohaven Ltd. | Stock-Other | 0.79% | — | — | |
| 30 | ADUS | Addus Homecare CORP | Stock-Other | 0.78% | — | — | |
| 31 | SGHT | Sight Sciences Inc | Stock-Other | 0.76% | — | +6.65% | |
| 32 | ERAS | Erasca Inc | Stock-Other | 0.43% | — | — | |
| 33 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.40% | — | -6.35% | |
| 34 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.26% | -0.69% | +192.64% | |
| 35 | RNTX | Rein Therapeutics Inc | Stock-Other | 0.25% | +0.11% | +6.18% | |
| 36 | ✓ | Mural Oncology Pub LTD Co | Stock-Other | 0.18% | — | -9.44% | |
| 37 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.15% | -0.07% | — | |
| 38 | IMNM | Immunome Inc | Stock-Other | 0.05% | — | -56.54% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | — | NEW | New buy |
| 2 | MGTX | MeiraGTx Holdings plc | — | NEW | New buy |
| 3 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 4 | JANX | Janux Therapeutics Inc | — | NEW | New buy |
| 5 | ROIV | Roivant Sciences Ltd. | — | NEW | New buy |
| 6 | MIRM | Mirum Pharmaceuticals Inc | — | NEW | New buy |
| 7 | KURA | Kura Oncology Inc | — | NEW | New buy |
| 8 | ✓ | Adc Therapeutics SA | — | NEW | New buy |
| 9 | ZYME | Zymeworks Inc | — | NEW | New buy |
| 10 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
| 11 | ICLR | ICON Public Limited Company | — | NEW | New buy |
| 12 | RCKT | Rocket Pharmaceuticals Inc | — | NEW | New buy |
| 13 | ACHC | Acadia Healthcare Co Inc | — | NEW | New buy |
| 14 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 15 | SDGR | Schrodinger Inc | — | NEW | New buy |
| 16 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 17 | TECX | Tectonic Therapeutic Inc | — | NEW | New buy |
| 18 | ISRG | Intuitive Surgical Inc | — | NEW | New buy |
| 19 | STTK | Shattuck Labs Inc | — | NEW | New buy |
| 20 | ABCL | Abcellera Biologics Inc | — | NEW | New buy |
| 21 | IMVT | Immunovant Inc | — | NEW | New buy |
| 22 | PRTA | Prothena Corporation plc | — | NEW | New buy |
| 23 | LIVN | LivaNova PLC | — | NEW | New buy |
| 24 | HAE | Haemonetics Corp/mass | — | NEW | New buy |
| 25 | 2655787D | Blueprint Medicines CORP | — | NEW | New buy |
| 26 | CRBP | Corbus Pharmaceuticals Holdi | — | NEW | New buy |
| 27 | CTMX | Cytomx Therapeutics Inc | — | NEW | New buy |
| 28 | CDNA | Caredx Inc | — | NEW | New buy |
| 29 | BHVN | Biohaven Ltd. | — | NEW | New buy |
| 30 | ADUS | Addus Homecare CORP | — | NEW | New buy |
| 31 | SGHT | Sight Sciences Inc | — | NEW | New buy |
| 32 | ERAS | Erasca Inc | — | NEW | New buy |
| 33 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 34 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| 35 | RNTX | Rein Therapeutics Inc | — | NEW | New buy |
| 36 | ✓ | Mural Oncology Pub LTD Co | — | NEW | New buy |
| 37 | PLRX | Pliant Therapeutics Inc | — | NEW | New buy |
| 38 | IMNM | Immunome Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Prosight Management, LP reported a total U.S. public equity portfolio value of $580.4M across 38 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
LKFT
市值: $33.0M
During Q1 2025, Prosight Management, LP's top holdings by market value included LKFT (10.8%)、MGTX (8.2%)、BBIO (6.9%). The largest single position, LKFT, represented 10.8% of total portfolio value.
In Q1 2025, Prosight Management, LP made 38 total portfolio adjustments, initiating 38 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.